NKGen Biotech, Inc. financial data

Symbol
NKGN, NKGNW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3001 Daimler St,, Santa Ana, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Graf Acquisition Corp. IV (to 9/29/2023)
Latest financial report
10-Q - Q2 2024 - Sep 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 9.05 % +32.5%
Debt-to-equity -133 % -173%
Return On Equity 158 % -36.5%
Return On Assets -479 % -1022%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 35.4M shares +61.6%
Common Stock, Shares, Outstanding 25.8M shares
Entity Public Float 62.8M USD -62.3%
Common Stock, Value, Issued 3K USD
Weighted Average Number of Shares Outstanding, Basic 24.2M shares +81.5%
Weighted Average Number of Shares Outstanding, Diluted 24.2M shares +81.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Cost of Revenue 0 USD
Research and Development Expense 14.3M USD -23.8%
General and Administrative Expense 17.1M USD +43.4%
Costs and Expenses 31.4M USD +12.8%
Operating Income (Loss) -31.4M USD +12.9%
Nonoperating Income (Expense) 5.95M USD -40.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -80M USD -116%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -88.3M USD -92.3%
Earnings Per Share, Basic -5.08 USD/shares +8.63%
Earnings Per Share, Diluted -5.08 USD/shares +8.63%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 79K USD +90.6%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 2K USD
Assets, Current 1.25M USD +1551%
Deferred Income Tax Assets, Net 15.4K USD
Property, Plant and Equipment, Net 13.9M USD
Operating Lease, Right-of-Use Asset 450K USD
Assets 15.6M USD -75.4%
Accounts Payable, Current 12.7M USD +7671%
Employee-related Liabilities, Current 773K USD
Accrued Liabilities, Current 1.52M USD -69.8%
Liabilities, Current 51.4M USD +716%
Deferred Income Tax Liabilities, Net 33K USD
Operating Lease, Liability, Noncurrent 316K USD
Liabilities 85.4M USD +813%
Retained Earnings (Accumulated Deficit) -184M USD -2050%
Stockholders' Equity Attributable to Parent -69.7M USD -464%
Liabilities and Equity 15.6M USD -75.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.03M USD +17.9%
Net Cash Provided by (Used in) Financing Activities 4.01M USD -27.9%
Net Cash Provided by (Used in) Investing Activities 35K USD
Common Stock, Shares Authorized 500M shares +25%
Common Stock, Shares, Issued 25.8M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8K USD -98.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 329K USD -77.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 120K USD
Deferred Tax Assets, Valuation Allowance 33.7M USD +41.6%
Deferred Tax Assets, Gross 1.03M USD +98.4%
Operating Lease, Liability 500K USD
Depreciation 800K USD -50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -88.3M USD -105%
Lessee, Operating Lease, Liability, to be Paid 608K USD
Property, Plant and Equipment, Gross 18.2M USD
Operating Lease, Liability, Current 154K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 249K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 242K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.22 pure
Lessee, Operating Lease, Liability, to be Paid, Year Three 249K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.8M USD +27.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +900%
Unrecognized Tax Benefits 551K USD +36.7%
Additional Paid in Capital 125M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 295K USD -2.96%
Deferred Tax Assets, Net of Valuation Allowance 34.1M USD +39.2%
Share-based Payment Arrangement, Expense 4.11M USD +11.7%
Interest Expense 1.07M USD +3044%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%